Showing 126–150 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Yihui Zhou, Hongxia Niu
… TB (RR-TB) posing critical challenges. Conventional longer regimens are characterized by suboptimal effectiveness, high toxicity, and poor tolerability. Consequently, there is an urgent demand for more effective, safer, shorter regimens with enhanced tolerability to replace trad…
Aslan AF, Ortaköylü MG, Bağcı BA, Toprak S
…eatment.The aim of this study was to evaluate the treatment regimens and results of H-resistant pulmonary TB patients. Methods We retrospectively evaluated treatment regimens and results of 188 H-resistant pulmonary TB patients who were treated in our center between January 2015 …
Victor Babawale, Clement Adesigbin, Corinne S Merle, Vanessa Veronese, Fatimata Bintou Sall, et al.
The introduction of significantly shorter, all-oral regimens has significantly shifted the management of drug-resistant tuberculosis (DR-TB) towards a more tolerable and patient-centred therapeutic approach that aims to enhance treatment adherence, clinical outcomes, and quality …
Olayanju O, Esmail A, Limberis J, Dheda K
…anid and bedaquiline in drug-resistant tuberculosis (DR-TB) regimens. Prospective long-term outcome data, including in HIV-infected persons, are unavailable.We prospectively followed up 122 South African patients (52.5% HIV-infected) with DR-TB and poor prognostic features betwee…
Fu L, Weng T, Sun F, Zhang P, Li H, et al.
…ive, and toxic treatment until short-course injectable-free regimens emerged. However, the new WHO-recommended regimens might be less feasible in the real-world setting. Here, we evaluated two optimized all-oral short-course regimens in China. Methods From April 2019 to August 20…
Arto Yuwono Soeroto, Aga Purwiga, Hendarsyah Suryadinata, Bachti Alisjahbana, Afiatin Makmun, et al.
…tudy analyzed 170 DR-TB individuals treated with BPaLM/BPaL regimens at Hasan Sadikin General Hospital, a tertiary hospital in West Java, Indonesia from January 2024 to January 2025. Data were collected from the Indonesian National DR-TB registers. A successful treatment outcome …
Ndjeka N, Campbell JR, Meintjes G, Maartens G, Schaaf HS, et al.
…lowed by 200 mg three times a week for 22 weeks. To compare regimens, patients were exactly matched on HIV and ART status, previous tuberculosis treatment history, and baseline acid-fast bacilli smear and culture result, while propensity score matched on age, sex, province of tre…
Keon Young Lee, Miri Hyun, Ji Yeon Lee, Hyun Ah Kim
…of drug-resistant tuberculosis (TB). Bedaquiline-containing regimens are recommended for multidrug-resistant pulmonary TB, but evidence regarding the optimal treatment for extrapulmonary manifestations such as spinal TB remains limited.Herein, we report two cases of drug-resistan…
Chang KC, Nuermberger E, Sotgiu G, Leung CC
Since standardized rifampin-based first-line regimens and fluoroquinolone-based second-line regimens were used to treat tuberculosis (TB), unfortunately without timely modification according to the drug resistance profile, TB and drug-resistant disease are still important public …
Kumar G, Kumar M, Muni S, Kumar R, Shankar M, et al.
…tidrug resistance pulmonary tuberculosis on all-oral longer regimens took one spot and one morning sample of sputum as per standard protocol after completing two months of all-oral longer regimens and culturing it in liquid broth using Mycobacterium Growth Indicator Tube (MGIT) 9…
Sodeifian F, Zangiabadian M, Arabpour E, Kian N, Yazarlou F, et al.
…ing the clinical and microbiological efficacy and safety of regimens containing TG in patients with drug susceptibility testing (DST)-confirmed MDR A. baumannii , published until December 30, 2022. Observational studies were included if they reported clinical and microbiological …
Soedarsono S, Mertaniasih NM, Kusmiati T, Permatasari A, Subay S, et al.
…ucted to analyze the efficacy and safety between individual regimens containing bedaquiline with delamanid and bedaquiline without delamanid. Methods This was an observational analytic study with a retrospective design in MDR-TB patients treated with individual regimens containin…
Sinha P, Jacobson KR, Horsburgh CR Jr, Acuña-Villaorduña C
…culosis (MDR-TB) has historically required longer treatment regimens that were associated with higher unfavorable outcomes and side effects rates compared with drug susceptible TB (DS-TB). During the last decade, several studies conducted mostly in high-incidence settings have sh…
О В Родина, Sergey Evgenievich Borisov, Diana Ivanova
<b>Background:</b> The new regimens for MDR TB, presented by WHO in 2018, August, are promising, but their feasibility, depended on safety, isn’t tested enough in real-life conditions. <b>Methods:</b> The retrospective/prospective study include 205 pts with pulmonary MDR TB (18-7…
Sarin R, Vohra V, Singla N, Singla R, Puri MM, et al.
…age regimen. Methods BDQ and DLM were used together to make regimens along with other drugs where four effective anti TB drugs could not be prescribed as per WHO recommendations. Patients were followed up for sputum smear and culture conversion and adverse events during the treat…
Kempker RR, Mikiashvili L, Zhao Y, Benkeser D, Barbakadze K, et al.
…rtile range [IQR], 4-4) and delamanid-based (4; IQR, 3.5-5) regimens were similar. Rates of acquired drug resistance were significantly higher among patients receiving delamanid versus bedaquiline (36% vs 10%, respectively; P Conclusions Among patients with MDR-TB, bedaquiline-ba…
Cheraghi M, Amiri M, Andarzgoo S, Zarei F, Seghatoleslami ZS, et al.
…proaches. The persistence of MDR-TB has led to a demand for regimens that are more effective in improving treatment outcomes and controlling transmission. This systematic review and meta-analysis sought to examine the efficacy of linezolid (LZD) and bedaquiline (BDQ) in MDR-TB tr…
Solomonia N, Vacharadze K
…the all anti-TB drugs and to build an appropriate treatment regimens based on complete individual DST profile in timely manner. Initial TB treatment regimen prescribed based on gDST results not in all cases may be compliant with complete DST profile, which may be detected based o…
Beijing Chest Hospital
WHO has recommended that multidrug-resistant tuberculosis (MDR-TB, defined as resistance to at least isoniazid (H) and rifampicin (R) be addressed as a public health crisis and enhance capacity to deliver effective treatment and care. According to the 2018 WHO TB Report, the over…
Liang Li
The purpose of this study is to monitor and evaluate the safety and effectiveness of Delamanid in combination with an optimal background regimen (OBR) of anti-TB drugs for treatment of MDR-TB. This is a single-arm, multicenter, phase #, open-label trial to evaluate the safety an…
Simbarashe G Takuva, MD, MSc.
This study aims to assess quabodepistat-based treatment regimens for RR/MDR-TB. The study will enroll adults and adolescents with rifampicin-resistant or multidrug-resistant pulmonary TB. The main goal is to see if a new drug called quabodepistat, when combined with other TB drug…
Eden Suryoiman Winoto, Didi Candradikusuma
The continuing spread of Multidrug-Resistant Tuberculosis (MDR-TB), which is defined as TB that shows resistance to both isoniazid and rifampicin, become one of the most urgent and difficult challenges in TB control. In Indonesia, the estimated total DR-TB case incidence of 24,00…
Gwanita Nawariantina Perangin-angin, Bintang Yinke Magdalena Sinaga, Parluhutan Siagian, Putri Chairani Eyanoer
ABSTRACT Background: Indonesia ranked 2nd around the world for TB cases with case population continue increasing. In 2018, Shorter Treatment Regimen (STR) was introduced as a new regimen for treating MDR-TB patient. The aim of this study is to determine factors associated with tr…
Dumitru Chesov, Jan Heyckendorf, Maja Reiman, Sofia Alexandru, Ana Donica, et al.
…tients who received bedaquiline containing MDR-TB treatment regimens in the Republic of Moldova. <b>Methods:</b> We systematically analyzed the national electronic TB database and performed a retrospective comparison of treatment outcome in patients with MDR-TB who completed trea…
Christian Lienhardt, MD
…mended by WHO. Patients will be treated with one of the two regimens that will be randomly allocated. A total of 2070 patients will ne recruited in the trial and followed-up for a duration of 2 years. The trial is multicentre, and conducted in 5 countries in Africa.